Showing results (41-50 of 3,350) with videos related to

Sort By:
Pageof 335
The Lancet. Oncology|March 26, 2011
A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysisTrupti Paranjape, Helen Heneghan, Robert Lindner, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 studyKenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
The Lancet. Oncology|May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 studyKohei Shitara, Hiroji Iwata, Shunji Takahashi, et al.
The Lancet. Oncology|June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
The Lancet. Oncology|June 5, 2019
Mapping a route to Indigenous engagement in cancer genomic researchKimiora L Henare, Kate E Parker, Helen Wihongi, et al.
The Lancet. Oncology|July 31, 2016
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trialFred Saad, Joan Carles, Silke Gillessen, et al.
The Lancet. Oncology|August 8, 2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trialBrian I Rini, Tanya B Dorff, Paul Elson, et al.
The Lancet. Oncology|August 10, 2016
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational studyAnita Villani, Ari Shore, Jonathan D Wasserman, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
The Lancet. Oncology|April 4, 2021
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialThierry Andre, Mayur Amonkar, Josephine M Norquist, et al.
Pageof 335